Two No­var­tis sites stop man­u­fac­tur­ing can­cer ther­a­pies af­ter qual­i­ty is­sues

Af­ter find­ing some qual­i­ty is­sues at­trib­uted to its man­u­fac­tur­ing process, No­var­tis has halt­ed the pro­duc­tion of two of its ra­di­oli­gand ther­a­pies at sites in Italy and New Jer­sey, the com­pa­ny an­nounced Thurs­day.

The pro­duc­tion of Lu­tathera and Plu­vic­to will stop tem­porar­i­ly at its sites in Ivrea, Italy and Mill­burn, NJ. The moves come out of “an abun­dance of cau­tion” af­ter some qual­i­ty is­sues were iden­ti­fied. Pro­duc­tion is ex­pect­ed to re­sume with­in the next six weeks, No­var­tis said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.